Help Lift Their Burden

ILARIS for the treatment of active

ILARIS for the treatment of

Cryopyrin-Associated Periodic Syndromes

ILARIS® (canakinumab) is an interleukin-1β blocker indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) in adults and children aged 4 years and older including:

  • Familial Cold Autoinflammatory Syndrome (FCAS)
  • Muckle-Wells Syndrome (MWS)

ILARIS® (canakinumab) is indicated for the treatment of active Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older.

 
Imporatnt Safety Information